Alembic Pharma Q1FY27: Revenue +26%, PAT ₹173cr

Results snapshot: what changed in the June quarter

Alembic Pharmaceuticals reported a strong start to FY27, with broad-based growth across its major businesses in the quarter ended June 30, 2026. Consolidated revenue from operations rose 26% year-on-year (YoY) to ₹2,149.77 crore (also reported as ₹2,150 crore). Consolidated net profit increased 12.1% YoY to ₹173.07 crore.

Management attributed the revenue growth to strong performance in US generics, APIs and international markets. The company also indicated that pricing pressure continues in the US generics market, especially once exclusivity periods end. Alongside the numbers, Alembic made the audio recording of its post-results conference call available on its website.

Key financials: revenue, margins and profit

The company’s revenue growth outpaced profit growth in Q1FY27, reflecting higher costs and investments mentioned on the conference call. EBITDA for the quarter was reported at ₹274 crore in one update, while another transcript referenced EBITDA before R&D of ₹523 crore (₹5.23 billion) with margins around 24%. The company also disclosed Q1FY27 R&D spend at ₹186 crore (₹1.86 billion), around 9% of revenue.

Net profit for Q1FY27 was ₹173.07 crore, compared with ₹154.38 crore in the year-ago quarter. Revenue from operations was ₹2,149.77 crore versus ₹1,710.72 crore in Q1FY26 and ₹1,847.72 crore in Q4FY26.

Growth drivers: US formulations led the quarter

A key highlight was the company’s US generics business, which saw 49% YoY growth in the quarter. The performance was supported by bosutinib exclusivity and new launches, along with progress in filings and approvals. The company also cited volume growth and better manufacturing asset utilisation as contributing factors.

International generics grew 37% YoY, supported by volume growth, new launches, and improved asset utilisation. The API business grew 33% YoY and was described as exceeding initial guidance, backed by longer-term growth drivers.

Bosutinib exclusivity and what it means

On the earnings call, Managing Director Pranav Amin confirmed that Alembic has 180-day marketing exclusivity on bosutinib in the 100mg and 500mg strengths. That exclusivity was cited as one of the factors behind the sharp rise in US generics revenue.

The company also noted that US generics remains a market with persistent pricing pressure, and it flagged the potential for significant erosion after exclusivity periods. This is a key context point for investors tracking sustainability of quarterly outperformance.

Operating metrics: launches, approvals and portfolio size

Alembic provided multiple operating updates in the conference call transcript. It launched seven products during Q1FY27 and secured 10 regulatory approvals, along with four filings in the quarter. The company’s commercialised portfolio was stated at 185 products.

CFO G. Krishnan also said the reported 49% US growth includes a currency impact of about 10%, with constant currency growth estimated at about 38-39%.

Costs and margins: what management flagged

Management commentary pointed to several moving parts for FY27 margins. Gross margins were described as flat quarter-on-quarter and within the guided 70-75% range. The company cited rising solvent prices, product mix changes, and under-absorption due to maintenance upgrades in a facility as factors affecting gross margin.

Another element discussed was the US branded specialty business, which is in a soft launch phase and is expected to dilute margins by about 150 basis points for FY27. Higher depreciation and interest costs were also referenced, linked to US branded product acquisitions and increased working capital.

FY27 outlook: guidance raised after strong Q1

Alembic had initially projected low double-digit growth of around 10-12% for FY27. Following the Q1 performance, it lifted its full-year revenue growth outlook to the mid-teen range. For the US generics business, management revised the growth guidance upward from low-teens to mid-to-high teens for FY27.

On margins, the CFO reiterated that core business margins are expected to improve to the high-teens, partly offset by the expected margin dilution from the US branded business. The company’s overall reported EBITDA margin was guided to be broadly flat to slightly better than FY26 levels, depending on the branded business ramp-up.

Investor communication: conference call audio and transcript availability

Alembic Pharmaceuticals said it has uploaded the audio of its August 4, 2026 post-results conference call to its website. The company noted that the audio file is hosted in the quarterly results section and remains accessible for investors and analysts.

Link provided by the company: https://alembicpharmaceuticals.com/quarterly-results

Why the update matters for pharma investors

The quarter stands out for the combination of strong headline revenue growth and a guidance raise for FY27, anchored by US business momentum. At the same time, the company’s commentary keeps focus on typical US generics risks, including price erosion after exclusivity.

For investors tracking Indian pharma earnings, the results also show how a single product exclusivity in the US, combined with a steady pipeline of approvals and launches, can materially move quarterly growth. Management’s disclosures around currency impact, R&D intensity (9% of revenue), and margin headwinds provide additional inputs for assessing the quality of growth.

Conclusion

Alembic’s Q1FY27 results showed 26% YoY growth in revenue to ₹2,149.77 crore and a 12.1% rise in net profit to ₹173.07 crore, with a sharp pickup in US generics and healthy growth in APIs and international markets. The company has raised its FY27 growth outlook to the mid-teens and lifted its US generics growth guidance to the mid-to-high teens. Investors will watch how growth holds up beyond exclusivity-led quarters and how margins evolve as the US branded specialty business ramps up through FY27.